Literature DB >> 1536950

Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears.

H van Kamp1, C de Pijper, M Verlaan-de Vries, J L Bos, C H Leeksma, H Kerkhofs, R Willemze, W E Fibbe, J E Landegent.   

Abstract

We performed a longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia and a follow-up of at least 2.5 years after diagnosis. Point mutations at codons 12, 13, and 61 of the N-ras oncogene were analyzed after in vitro amplification of N-ras specific sequences followed by dot-blot hybridization. Lysed cells scraped from archived blood and bone marrow smears were used as template for a polymerase chain reaction. In 3 of 90 patients tested (3.3%), a mutation in codon 12 could be detected in the most recent blood smears. All available blood and bone marrow samples of these patients were subsequently analyzed for the occurrence of that particular mutation. In all three cases the mutation was not detectable at diagnosis, but was acquired later during the course of the disease. In two of these patients this event was associated with rapid deterioration and transformation to acute leukemia. However, the third patient showed a protracted course during a period of 5 years after acquisition of the mutation. These results indicate that activation of the N-ras protooncogene in these three patients represents a secondary phenomenon associated with disease progression in some cases, but compatible with stable disease in others.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536950

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

Review 2.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

3.  The clonal origins of leukemic progression of myelodysplasia.

Authors:  T Kim; M S Tyndel; H J Kim; J-S Ahn; S H Choi; H J Park; Y-K Kim; D-H Yang; J-J Lee; S-H Jung; S Y Kim; Y H Min; J-W Cheong; S K Sohn; J H Moon; M Choi; M Lee; Z Zhang; D D H Kim
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

Review 4.  Biology and treatment of myelodysplastic syndromes--developments in the past decade.

Authors:  R Willemze; W E Fibbe; J H Falkenburg; J C Kluin-Nelemans; P M Kluin; J E Landegent
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

5.  Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.

Authors:  Aref Al-Kali; Alfonso Quintás-Cardama; Raja Luthra; Carlos Bueso-Ramos; Sherry Pierce; Tapan Kadia; Gautam Borthakur; Zeev Estrov; Elias Jabbour; Stefan Faderl; Farhad Ravandi; Jorges Cortes; Ayalew Tefferi; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2013-03-20       Impact factor: 10.047

Review 6.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.